anidulafungina mylan 100 mg
laboratori fundacio dau - spania - anidulafunginum - pulb. pt. conc. pt.sol. perf. - 100mg - antimicotice de uz sistemic alte antimicotice sistemice
anidulafungina fresenius kabi 100 mg
laboratori fundacio dau - spania - anidulafunginum - pulb. pt. conc. pt. sol. perf. - 100mg - antimicotice de uz sistemic alte antimicotice sistemice
anidulafungina accord 100 mg
pharmidea sia - letonia - anidulafunginum - pulb. pt. conc. pt. sol. perf. - 100mg - antimicotice de uz sistemic alte antimicotice sistemice
anidulafungina teva 100 mg
teva operations poland sp. z.o.o - polonia - anidulafunginum - pulb. pt. conc. pt. sol. perf. - 100mg - antimicotice de uz sistemic alte antimicotice sistemice
anidulafungina sandoz 100 mg
pharmidea sia - letonia - anidulafunginum - pulb. pt. conc. pt. sol. perf. - 100mg - antimicotice de uz sistemic alte antimicotice sistemice
ecalta
pfizer europe ma eeig - anidulafungin - candidoza - antimicotice pentru uz sistemic - tratamentul candidozei invazive la pacienții adulți și copii cu vârsta de 1 lună până la < 18 ani.
anidulafungina rompharm 100 mg
rompharm company s.r.l. - romania - anidulafunginum - conc. pt. sol. perf. - 100mg - antimicotice de uz sistemic alte antimicotice sistemice
ecalta 100mg
pfizer manufacturing belgium n.v. - belgia - anidulafunginum - pulb. pt. conc. pt. sol. perf. - 100mg - antimicotice de uz sistemic alte antimicotice sistemice
micafungin rompharm 100 mg
rompharm company s.r.l. - romania - micafunginum - pulb. pt. conc. pt. sol. perf. - 100mg - antimicotice de uz sistemic alte antimicotice sistemice
cancidas (previously caspofungin msd)
merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimicotice pentru uz sistemic - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.